Accessibility of high-cost anti-cancer medicines in China_Chinese Journal of Evidence-Based Medicine

Authors：

ZHOU Yanping ¹ , WANG Haigang ² , HU Qinghe ¹ , ZHOU Runshi ¹ , CHENG Lishan ³ , KANG Fenheng ⁴ ,  SUN Jing ⁵

1. Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, P.R.China;
2. Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing, 100730, P.R.China;
3. Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, 610052, P.R.China;
4. National Institute of Geriatrics, Beijing Hospital, Beijing, 100730, P.R.China;
5. School of Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, P.R.China;

Corresponding?author：

SUN Jing, Email: sunjing@sph.pumc.edu.cn

Keywords：

Malignant tumor; High-cost anti-cancer medicines; Accessibility; Influence factors

DOI：

10.7507/1672-2531.201703028

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Malignant tumors are the major diseases which threat human beings. Anti-cancer medicines play important roles in the treatment of malignant tumors, especially for the new targeted therapies. They bring the life hope for cancer patients who were sentenced to death, and improve quality of life, and some patients may achieve normal lifetime. However, the new anti-cancer medicines are usually too expensive to afford, and most of them have not yet been included in Chinese public health security system, the accessibility of the new anti-cancer medicines is seriously limited. This paper introduces the accessibility of high-cost anti-cancer medicines in China, analyzes the influence factors, and proposes policy recommendations to improve the accessibility of high-cost anti-cancer medicines in China.

Citation： ZHOU Yanping, WANG Haigang, HU Qinghe, ZHOU Runshi, CHENG Lishan, KANG Fenheng, SUN Jing. Accessibility of high-cost anti-cancer medicines in China. Chinese Journal of Evidence-Based Medicine, 2017, 17(7): 862-868. doi: 10.7507/1672-2531.201703028 Copy

1.	Health WCoMa. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health: Geneva: World Health Organization, 2001.
2.	Organization PAH. Access to high-cost medicines in the Americans: situation, challenges and perspectives. Area of technology, health care and research, essential medicines and biologicals unit (THR/EM): Washington, D.C. 2010.
3.	國際人權文書. 第 14 號一般性意見: 享有能達到的最高健康標準的權利(第十二條). 2000. Available at: http://www. humanrights.cn/html/2014/1_1009/1878.html.
4.	黃勇. 基于患者角度的我國基本藥物行為可及性研究. 中國醫藥指南, 2013, 11(22):721-723.
5.	WHO. Medicines strategy: framework for action in essential drugs and medicine policy 2000-2003. WHO: Genva, 2001.
6.	國家統計局. 2016 年全國居民收入穩步增長居民消費進一步改善. [2017-01-20]. Available at: http://www.stats.gov.cn/tjsj/ sjjd/201701/t20170120_1456174.html.
7.	中華慈善總會. Available at: http://www.chinacharityfederation.org/.
8.	Clinicaltrials. Available at: www.clinicaltrials.gov.
9.	健康界. 海南" 進口藥”特區: 國外癌癥新藥首次臨床應用. 搜狐健康. [2016-11-02]. Available at: http://mt.sohu.com/20161102/ n472097187.shtml.
10.	聯合國. 千年發展目標差距工作組 2012 年報告. Available at: http://www.un.org/zh/millenniumgoals/reports.shtml.
11.	藥品價格 315 網. Available at: https://www.315jiage.cn/.
12.	國家食品藥品監督管理總局. 藥物臨床實驗登記與信息公示平臺. Available at: http://www.chinadrugtrials.org.cn/.
13.	翁新愚. TRIPS 協約與藥品專利. 中國藥學雜志, 2003, 38(5):389-390.
14.	楊莉, 李野, 岳晨妍. 淺析《與貿易有關的知識產權協議》體制下的專利制度與藥品價格. 中國藥房, 2008, 19(10):721-723.
15.	Chee YL, 陳惜平. 知識產權與不太昂貴藥品的可及性: 一些亞洲國家的經驗. 第三世界網絡, 2007.
16.	國家食品藥品監督管理總局藥品審評中心化學仿制藥生物等效性與臨床試驗備案信息平臺. Available at: http://be. chinadrugtrials.org.cn/index.dhtml.
17.	國務院辦公廳. 國務院辦公廳關于進一步改革完善藥品生產流通使用政策的若干意見(國辦發[2017]13號).[2017-02-09]. Available at: http://www.gov.cn/zhengce/content/2017-02/09/ content_ 5166743.htm.
18.	劉晶晶, 武志昂. 從政府規制理論看" Bolar 例外”. 中國藥師, 2016, 19(7): 1382-1384.
19.	Todd S. Pfizer's Lipitor getting hit with a new onslaught of generic rivals. Available at: http://www.nj.com/business/index.ssf/ 2012/06/pfizers_lipitor_getting_hit_wi.html.
20.	Teerawattananon Y, Tritasavit N. A learning experience from price negotiations for vaccines. Vaccine, 2015, 33(suppl1): 11-12.
21.	The Ministry of Public Health and the National Health Security Office Thailand. The 10 burning questions on the government use of patents on the four anti-cancer drugs in Thailand. Nonthaburi: Ministry of Public Health, 2008.
22.	Wibulpolprasert S, Chokevivat V, Oh C, et al. Government use licenses in Thailand: the power of evidence, civil movement and political leadership. Global Health, 2011, 7(7): 32-39.
23.	袁雪丹, 傅鴻鵬. 國外藥品價格談判機制對中國的啟示. 衛生經濟研究, 2015, 11(34): 29-33.
24.	Ford N, Wilson D, Costa Chaves G, et al. Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand. AIDS, 2007, 21(Suppl 4): 21-29.
25.	樓杜鵑. 藥品專利 Bolar 例外條款的發展和應用. 中國發明與專利, 2011, 7(6): 80-82.
26.	彭輝. 藥品平行進口的福利效應評價: 基于瑞典的實證分析. 北京: 第一屆全國博士生知識產權學術論壇, 2010.
27.	孫靜, 蔣鋒, 趙琪, 等. 一個發展中國家實現高值救命藥全民可及的成功經驗及對我國的啟示. 中國藥房, 2017, 28(3): 289-294.
28.	Anita K. Wagner MB, Anthony D, et al. Chapter 4 – Innovation to ensure better access to medicines Authors. Case studies: Rosarin Sruamsiri, Netnapis Suchonwanich (E2 Access Program in Thailand). In: Medicines in Health Systems: Advancing access, affordability and appropriate use. WHO: Geneva, 2014.
29.	孫靜, 金平閱, 張春瑜. 衛生立法的國際經驗對我國的啟示. 中國衛生政策研究, 2016, 9(10): 66-71.
30.	孫靜, 趙紅艷, 馬麗平, 等. 我國專利保護制度下涉及重大公共健康問題高價藥品的經濟可及性. 中國循證醫學雜志, 2014, 14(5): 509-516.
31.	Tannock IF, Hickman JA. Limits to Personalized Cancer Medicine. N Engl J Med, 2016, 375(13): 1289-1294.
32.	Prasad V. Perspective: The precision-oncology illusion. Nature, 2016, 537(7619): 63.

1. Health WCoMa. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health: Geneva: World Health Organization, 2001.
2. Organization PAH. Access to high-cost medicines in the Americans: situation, challenges and perspectives. Area of technology, health care and research, essential medicines and biologicals unit (THR/EM): Washington, D.C. 2010.
3. 國際人權文書. 第 14 號一般性意見: 享有能達到的最高健康標準的權利(第十二條). 2000. Available at: http://www. humanrights.cn/html/2014/1_1009/1878.html.
4. 黃勇. 基于患者角度的我國基本藥物行為可及性研究. 中國醫藥指南, 2013, 11(22):721-723.
5. WHO. Medicines strategy: framework for action in essential drugs and medicine policy 2000-2003. WHO: Genva, 2001.
6. 國家統計局. 2016 年全國居民收入穩步增長居民消費進一步改善. [2017-01-20]. Available at: http://www.stats.gov.cn/tjsj/ sjjd/201701/t20170120_1456174.html.
7. 中華慈善總會. Available at: http://www.chinacharityfederation.org/.
8. Clinicaltrials. Available at: www.clinicaltrials.gov.
9. 健康界. 海南" 進口藥”特區: 國外癌癥新藥首次臨床應用. 搜狐健康. [2016-11-02]. Available at: http://mt.sohu.com/20161102/ n472097187.shtml.
10. 聯合國. 千年發展目標差距工作組 2012 年報告. Available at: http://www.un.org/zh/millenniumgoals/reports.shtml.
11. 藥品價格 315 網. Available at: https://www.315jiage.cn/.
12. 國家食品藥品監督管理總局. 藥物臨床實驗登記與信息公示平臺. Available at: http://www.chinadrugtrials.org.cn/.
13. 翁新愚. TRIPS 協約與藥品專利. 中國藥學雜志, 2003, 38(5):389-390.
14. 楊莉, 李野, 岳晨妍. 淺析《與貿易有關的知識產權協議》體制下的專利制度與藥品價格. 中國藥房, 2008, 19(10):721-723.
15. Chee YL, 陳惜平. 知識產權與不太昂貴藥品的可及性: 一些亞洲國家的經驗. 第三世界網絡, 2007.
16. 國家食品藥品監督管理總局藥品審評中心化學仿制藥生物等效性與臨床試驗備案信息平臺. Available at: http://be. chinadrugtrials.org.cn/index.dhtml.
17. 國務院辦公廳. 國務院辦公廳關于進一步改革完善藥品生產流通使用政策的若干意見(國辦發[2017]13號).[2017-02-09]. Available at: http://www.gov.cn/zhengce/content/2017-02/09/ content_ 5166743.htm.
18. 劉晶晶, 武志昂. 從政府規制理論看" Bolar 例外”. 中國藥師, 2016, 19(7): 1382-1384.
19. Todd S. Pfizer's Lipitor getting hit with a new onslaught of generic rivals. Available at: http://www.nj.com/business/index.ssf/ 2012/06/pfizers_lipitor_getting_hit_wi.html.
20. Teerawattananon Y, Tritasavit N. A learning experience from price negotiations for vaccines. Vaccine, 2015, 33(suppl1): 11-12.
21. The Ministry of Public Health and the National Health Security Office Thailand. The 10 burning questions on the government use of patents on the four anti-cancer drugs in Thailand. Nonthaburi: Ministry of Public Health, 2008.
22. Wibulpolprasert S, Chokevivat V, Oh C, et al. Government use licenses in Thailand: the power of evidence, civil movement and political leadership. Global Health, 2011, 7(7): 32-39.
23. 袁雪丹, 傅鴻鵬. 國外藥品價格談判機制對中國的啟示. 衛生經濟研究, 2015, 11(34): 29-33.
24. Ford N, Wilson D, Costa Chaves G, et al. Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand. AIDS, 2007, 21(Suppl 4): 21-29.
25. 樓杜鵑. 藥品專利 Bolar 例外條款的發展和應用. 中國發明與專利, 2011, 7(6): 80-82.
26. 彭輝. 藥品平行進口的福利效應評價: 基于瑞典的實證分析. 北京: 第一屆全國博士生知識產權學術論壇, 2010.
27. 孫靜, 蔣鋒, 趙琪, 等. 一個發展中國家實現高值救命藥全民可及的成功經驗及對我國的啟示. 中國藥房, 2017, 28(3): 289-294.
28. Anita K. Wagner MB, Anthony D, et al. Chapter 4 – Innovation to ensure better access to medicines Authors. Case studies: Rosarin Sruamsiri, Netnapis Suchonwanich (E2 Access Program in Thailand). In: Medicines in Health Systems: Advancing access, affordability and appropriate use. WHO: Geneva, 2014.
29. 孫靜, 金平閱, 張春瑜. 衛生立法的國際經驗對我國的啟示. 中國衛生政策研究, 2016, 9(10): 66-71.
30. 孫靜, 趙紅艷, 馬麗平, 等. 我國專利保護制度下涉及重大公共健康問題高價藥品的經濟可及性. 中國循證醫學雜志, 2014, 14(5): 509-516.
31. Tannock IF, Hickman JA. Limits to Personalized Cancer Medicine. N Engl J Med, 2016, 375(13): 1289-1294.
32. Prasad V. Perspective: The precision-oncology illusion. Nature, 2016, 537(7619): 63.

Previous Article
Introduction of Core Outcome Set-STAndards for Reporting (COS-STAR)

Chinese Journal of Evidence-Based Medicine

Accessibility of high-cost anti-cancer medicines in China

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content